Jula K. Inrig

Chimeric Antigen Receptor-T Cell (CAR-T Cell) Therapy in Advanced Renal Cell Carcinoma

Brian Mark Churchill, Pallavi Patri, Jula K. Inrig, Anju Gopan, Ekaterina Vorozheikina, Luis Mendoza, Lara Kristina Donato & Ruma Pal Ghosh · International Research Journal of Oncology · 2021

With introduction of immunotherapy, the treatment of advanced renal cell carcinoma has undergone a substantial change. Immunotherapeutic agents including nivolumab, ipilimumab, pembrolizumab, have been introduced and approved for therapy of this life-threatening malignancy. Chime...

Open access Research Article

TNF-α, TNF Receptors and Their Complex Implications in Therapy

Brian Mark Churchill, Pallavi Patri, Rashna Cama & Jula K. Inrig · Asian Journal of Immunology · 2020

Tumor necrosis factor alpha (TNF-α), also called cachectin or cachexin, is a naturally occurring cytokine produced by activated macrophages and monocytes, and to a smaller scale by T-lymphocytes, B-lymphocytes, fibroblasts and astrocytes. It has both inflammatory and immunomodula...

Open access Research Article